Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin monotherapy (low certainty).
1 finding from 1 review
Remission · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly‐onset focal onset or generalised tonic‐clonic seizures
Sodium valproate showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin monotherapy (moderate certainty).
1 finding from 1 review
Total lesion area divided by total surface area (visual) · Patients with early caries lesions in permanent teeth (non-fluoridated water area)
Adding CPP-ACP to fluorides did not significantly change the lesion-area outcome for smooth-surface early caries lesions versus fluorides alone; not GRADE-rated.
1 finding from 1 review
Time to treatment withdrawal · people with epilepsy
VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation · people with epilepsy
It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with epilepsy
VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
ACR 50 response of DMARDs naive patients Number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
1 finding from 1 review
ACR 50 response of MTX inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of DMARDs naive patients number of withdrawals · patients with rheumatoid arthritis
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of MTX inadequate responders number of withdrawals · patients with rheumatoid arthritis
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs inadequate responders number of withdrawals · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with nicotine replacement therapy monotherapy (high certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline may leads to lower SAEs compared with nicotine replacement therapy monotherapy (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
1 finding from 1 review
Cardiac SAEs · people who smoke
1 finding from 1 review